Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue... Show more
a development stage company, which manufactures surgical and medical instruments
Industry PharmaceuticalsOther
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RFDI | 91.75 | 0.68 | +0.75% |
| First Trust RiverFront Dyn Dev Intl ETF | |||
| GSIE | 47.45 | 0.33 | +0.70% |
| Goldman Sachs ActiveBeta® Intl Eq ETF | |||
| SPYH | 56.50 | 0.34 | +0.61% |
| NEOS S&P 500 Hedged Equity Income ETF | |||
| MYHC | 24.87 | -0.01 | -0.04% |
| State Street®My2029 HighYield CrptBdETF | |||
| XPH | 67.51 | -0.50 | -0.74% |
| State Street® SPDR® S&P® PhrmctlsETF | |||
A.I.dvisor indicates that over the last year, PLSE has been loosely correlated with NVST. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PLSE jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To PLSE | 1D Price Change % | ||
|---|---|---|---|---|
| PLSE | 100% | -2.43% | ||
| NVST - PLSE | 39% Loosely correlated | -1.24% | ||
| CERS - PLSE | 38% Loosely correlated | +1.22% | ||
| CLPT - PLSE | 32% Poorly correlated | +1.78% | ||
| ARAY - PLSE | 32% Poorly correlated | +2.96% | ||
| TMCI - PLSE | 32% Poorly correlated | +3.68% | ||
More | ||||
| Ticker / NAME | Correlation To PLSE | 1D Price Change % |
|---|---|---|
| PLSE | 100% | -2.43% |
| Pharmaceuticals: Other industry (50 stocks) | 33% Poorly correlated | +0.11% |
| Pharmaceuticals industry (155 stocks) | 9% Poorly correlated | -0.04% |
PLSE broke above its upper Bollinger Band on September 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 59 similar instances where the stock broke above the upper band. In 54 of the 59 cases the stock fell afterwards. This puts the odds of success at 90%.
The 10-day RSI Indicator for PLSE moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 31 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 53 cases where PLSE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for PLSE turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 42 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLSE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved above the 0 level on September 09, 2026. You may want to consider a long position or call options on PLSE as a result. In 80 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
Following a +11.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLSE advanced for three days, in 228 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 112 of 131 cases where PLSE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PLSE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PLSE's P/B Ratio (38.023) is very high in comparison to the industry average of (4.965). P/E Ratio (0.000) is within average values for comparable stocks, (142.488). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.236). Dividend Yield (0.000) settles around the average of (0.015) among similar stocks. PLSE's P/S Ratio (3333.333) is very high in comparison to the industry average of (74.759).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.